L-arginine + heme arginate — Competitive Intelligence Brief

L-arginine + heme arginate (L-arginine + heme arginate) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Amino acid supplement / Nitric oxide donor. Area: Cardiovascular; Critical Care; Metabolic Disorders.

marketed Amino acid supplement / Nitric oxide donor Nitric oxide synthase (NOS); hemoglobin Cardiovascular; Critical Care; Metabolic Disorders Small molecule

Target snapshot

L-arginine + heme arginate (L-arginine + heme arginate) — Radboud University Medical Center. L-arginine and heme arginate work together to restore nitric oxide production and improve vascular function in patients with arginine deficiency or endothelial dysfunction.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
L-arginine + heme arginate TARGET	L-arginine + heme arginate	Radboud University Medical Center	marketed	Amino acid supplement / Nitric oxide donor	Nitric oxide synthase (NOS); hemoglobin
Oral L-arginine aspartate administration	Oral L-arginine aspartate administration	Ukrainian Medical Stomatological Academy	phase 3	Amino acid supplement / Nitric oxide donor	Nitric oxide synthase (NOS)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Amino acid supplement / Nitric oxide donor class)

1. Radboud University Medical Center · 1 drug in this class
2. Ukrainian Medical Stomatological Academy · 1 drug in this class